Early graft failure after adult living donor liver transplantation: A multicenter risk analysis and development of the early allograft failure in living donor liver transplantation (EAGLE-LDLT) model

View at publisher
Authors: Zhihao Li, Leonardo Centonze, Dimitri Raptis, Kris Ann Hervera Marquez, Ashwin Rammohan, Vasanthakumar Gunasekaran, Suyoung Hong, I Lun Chen, Jongman KIM, Shih-Chao Hsu, Elvan Onur Kırımker, Nobuhisa Akamatsu
+30 more Oren Shaked, Michele Finotti, Marcus Wei Xuan Yeow, Lara Genedy, Philipp Dutkowski, Silvio Nadalin, Markus U Boehnert, Wojciech Grzegorz Polak, Guan Huei Lee, Abhishek Mathur, Benjamin Samstein, J. Emond, Giuliano Testa, Kim M. Olthoff, Julie K. Heimbach, Timucin Taner, Tiffany CL Wong, Kiyoshi Hasegawa, D. Balci, Mark Cattral, G. Sapisochin, Nazia Selzner, Long-Bin Jeng, Jae‐Won Joh, Chao-Long Chen, Kyung-Suk Suh, Stefano Di Sandro, Mohamed Rela, Dieter Broering, Pierre-Alain Clavien
Cited by: 1
References: 49

Abstract

Early allograft failure (EAF) after living donor liver transplantation (LDLT) remains a clinical challenge. Existing prediction models developed for deceased donor transplantation poorly apply to LDLT due to distinct surgical and physiological factors. This study identifies clinical determinants of EAF and develops an LDLT-specific prediction model. We conducted a multicenter retrospective cohort study from 17 high-volume LDLT centers (January 2016-December 2020) with external validation at a tertiary center in Saudi Arabia (January 2015-December 2022). The primary outcome was EAF (graft loss or patient death ≤90 d). Multivariable mixed-effects logistic regression identified preoperative/intraoperative risk factors. The EAGLE-LDLT model was constructed using postoperative laboratory values. Performance was compared against established models (EAD, MEAF, A2ALL) using ROC analysis and decision curve analysis. The development cohort included 2944 adult LDLT recipients (67.7% male; median age 55 y; median MELD 14) with a 5.5% EAF rate. External validation included 1020 recipients (median MELD 21, 6.7% EAF). Independent risk factors for EAF were MELD (OR 1.06, 95% CI 1.04-1.08), donor BMI (OR 1.05, 95% CI 1.00-1.10), portal vein thrombosis (OR 1.73, 95% CI 1.13-2.63), and hepaticojejunostomy (OR 1.58, 95% CI 1.06-2.36). The EAGLE-LDLT model incorporating peak ALT (>468 U/L), peak INR (>1.9), and bilirubin (>3.5 mg/dL) and INR (>1.3) at POD7, demonstrated superior discrimination (AUC=0.81) compared with MEAF (AUC=0.77, p =0.004), EAD (AUC=0.67, p

Fields of Study & Subjects

Organ Transplantation Techniques and Outcomes Renal Transplantation Outcomes and Treatments Liver Disease and Transplantation

Publication details

Journal / source
Liver Transplantation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
32
Issue
7
Pages
1027–1039
Publication date
21 January 2026
Language
EN